PX'Therapeutics Plans New cGMP Biomanufacturing Facility
BNPZY | Quote | Chart | News | PowerRating -- PX'Therapeutics SA, formerly known as Protein'eXpert, announced the set up of an additional biomanufacturing unit dedicated to the production of therapeutic proteins and monoclonal antibodies in mammalian cells.
This facility, located in the company's Grenoble site, is mainly financed by loans from PX'Therapeutics' bank partners: BNP Paribas and Credit Cooperatif, with the support of OSEO Rhone-Alpes. The cGMP plant will be operational from April 2010 and will allow cell banking as well as preclinical and clinical manufacturing of biotherapeutics (scale: 100-200L). In parallel, PX'Therapeutics plans to upgrade the existing cGMP unit devoted to bacterial and yeast systems with a 100L bioreactor. The extension of the company's production capabilities is part of its development strategy and will mark its tenth anniversary.
More Information:
www.px-therapeutics.com
((Comments on this story may be sent to newsdesk@closeupmedia.com))
For full details on (BNPZY) BNPZY. (BNPZY) has Short Term PowerRatings at TradingMarkets. Details on (BNPZY) Short Term PowerRatings is available at This Link.
- Experts warn of early rollback of stimulus package in India - 02/09/10
- AGC & LCM Announce Second Adjournment of Reconvened Joint Special Meeting of Shareholders and LCM Provides Leverage Update - 02/04/10
- BNP Paribas sign contract with Gemalto - 02/03/10
- Miner's $658m lifeline to Zambia copper - 02/02/10
- Gemalto signs contract with BNP Paribas for EMV banking cards and personalisation services - 02/02/10
- More News >>
